Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

The firm’s lead candidate has shown promise in a pivotal rare disease study, setting it on track for an upcoming BLA catalyst which could lead to Aeglea’s first approved product.